The question of Medicare coverage of continuous glucose monitors (CGMs) is at a crossroads with the passage of 90 days since the district court decision in Whitcomb v. Burwell, which gave the government three months to respond to the May 26 decision. The stakes are enormous for makers of CGM systems if, as has been imputed, the incidence of diabetes generally continues to rise among those who will enroll in Medicare over the next two decades.
Read More
